Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | DRD4 | P21917 | 6/20 | 0.50 |
| ▸ | DRD3 | P35462 | 6/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13490679 | 0.81 | HRH3 (0.55) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL2822514 | 0.79 | ACHE (0.67) | HRH3ACHECHRM4KMT2A | |
| SCHEMBL3324632 | 0.77 | HRH3 (0.48) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL27759412 | 0.75 | CHRM4 (0.50) | CHRM4 | |
| SCHEMBL169363 | 0.74 | DRD2 (0.60) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL17936691 | 0.73 | DRD2 (0.52) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL171620 | 0.73 | HPGDS (0.55) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL13490551 | 0.73 | DRD2 (0.52) | DRD2DRD4DRD3HRH3ACHE | |
| SCHEMBL13490548 | 0.73 | DRD4 (0.52) | DRD2DRD4DRD3ACHECCR3 | |
| SCHEMBL7238995 | 0.72 | HRH3 (0.65) | DRD2DRD4HRH3ACHECHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547915-B | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-08-21 | — | — | CN | disclosed |
| US-8466153-B2 | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-18 | — | — | US | disclosed |
| EP-2091938-B1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| CN-101547915-A | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2091938-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008068277-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | DRD2 1/4885DRD4 13/4885DRD3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.